RIBOLIFE-B Buys Back 37,200 H Shares, Treasury Stock Rises to 1.01 Million

Bulletin Express10-22

On 22 October 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) executed an on-exchange repurchase of 37,200 H shares at prices between HKD 46.52 and HKD 47.20, translating to a volume-weighted average cost of HKD 46.85 per share. The aggregate outlay reached HKD 1.74 million.

Following the transaction, the company’s issued share count (excluding treasury shares) fell by 0.0219% to 169.55 million. Concurrently, treasury shares increased to 1.01 million, bringing total issued shares—including treasury stock—to 170.55 million.

The buyback forms part of a mandate approved on 5 June 2026 that authorises the repurchase of up to 17.06 million shares. To date, 1.01 million shares—equal to 0.59% of the issued shares outstanding on the mandate date—have been repurchased under this authority. Under Hong Kong listing rules, RIBOLIFE-B is restricted from issuing new shares or distributing treasury shares until 21 November 2026.

The board confirmed that the repurchase complied with all relevant listing rules, legal requirements and internal authorisations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment